Onasemnogene abeparvovec for treating type 1 spinal muscular atrophy has now been rescheduled into the work programme and is due to be discussed at the HST committee on 8 October 2020. Timelines and the expected publication date will be updated in due course.
The new timelines are subject to staff capacity and the ongoing management of the COVID-19 situation and we will continue to review our plans and update our stakeholders accordingly.